Skip to main content

Table 3 Baseline characteristics of the enrolled patients in AdaPT-study – compared to other trials

From: First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation

  VALUE[16] ASCOT-BPLA[17] DREAM[6, 38] AdaPT
  Valsartan Amlodipine Amlodipine Atenolol Ramipril Placebo ACEi Diuretic
  (n = 7649) (n = 7596) (n = 9639) (n = 9618) (n = 2.623) (n = 2.646) (n = 1.353) (n = 662)
Age (mean, years) 67.2 ± 8.2 67.3 ± 8.1 63.0 ± 8.5 63.0 ± 8.5 54.7 ± 10.9 54.7 ± 10.9 67.3 ± 10.4 66.5 ± 10.2
Male gender (%) 57.6 57.5 77 77 40.3 41.3 51.4 42.6
BMI (mean, kg/m 2 ) 28.6 ± 5.1 28.7 ± 5.0 28.7 ± 4.6 28.7 ± 4.5 30.9 ± 5.6 30.9 ± 5.7 29.9 ± 5.0 29.8 ± 4.8
   25–29.9 kg/m2 (%) n.a. n.a. n.a. n.a. n.a. n.a. 43.7 42.6
   ≥30 kg/m2 (%) n.a. n.a. n.a. n.a. n.a. n.a. 42.4 43.2
Waist-Hip-ratio         
   Men n.a. n.a. n.a. n.a. 0.96 ± 0.07 0.96 ± 0.07 0.99 ± 0.08 0.98 ± 0.07
   Women n.a. n.a. n.a. n.a. 0.86 ± 0.08 0.87 ± 0.08 0.90 ± 0.09 0.90 ± 0.08
History of Hypertension (%) 92.7* 92.0* 81* 81* 34.4 43.5 56.8 59.8
Heart rate (bpm) n.a. n.a. n.a. n.a. n.a. n.a. 74.0 ± 9.4 73.0 ± 9.8
Office systolic/diastolic BP (mmHg) 154.5 ± 19.0/87.4 ± 10.9 154.8 ± 19.0/87.6 ± 10.7 164.1 ± 18.1/94.8 ± 10.4 163.9 ± 18.0/94.5 ± 10.4 136.1 ± 18.6/83.4 ± 10.8 136.0 ± 18.1/83.4 ± 10.8 147.4 ± 15.9/87.3 ± 9.3 144.6 ± 15.3/86.5 ± 9.4
HbA1c (mean %) n.a. n.a. n.a. n.a. n.a. n.a. 5.6 ± 0.6 5.6 ± 0.7
Risk factors         
   Smoker (%) n.a. n.a. 33 32 44.1 45.0 15.6 13.6
   Dyslipidemia (%) n.a. n.a. n.a. n.a. 35.6 35.4 56.4 56.6
   Hyperuricemia (%) n.a. n.a. n.a. n.a. n.a. n.a. 21.7 23.0
   MAU (%) n.a. n.a. n.a. n.a. n.a. n.a. 6.2 5.4
   CHD (%) 45.6 46.0 n.a. n.a. exclusion 13.9 14.2
   Stroke/TIA (%) 19.8 19.8 n.a. n.a. exclusion exclusion
Drug therapy         
   Aspirin or antiplatelet agents (%) n.a. n.a. 19 19 14.3 14.3 27.7 21.9
   Thiazide diuretics (%) 35.9 35.1 n.a. n.a. 9.5 10.0 0.4 0
   Nonthiazide diuretics (%)    n.a. n.a. 5.9 5.6 0 0
   ACEi 41.3 41.4 n.a. n.a.    0 0.6
   ARBs (%) 10.7 10.6 n.a. n.a. 5.6 5.3 0.9 1.2
   Betablockers (%) 32.7 33.7 n.a. n.a. 17.2 17.5 0.3 0
   CCBs (%) 41.7 40.2 n.a. n.a. 12.8 12.9 18.6 15.3
   Alphablockers (%) 7.1 6.5 n.a. n.a. 1.9 2.2 2.1 2.0
   Statins (%) n.a. n.a. 11** 10** 12.4 13.5 19.4 17.4
   Fibrates (%) n.a. n.a.    2.1 2.3 0.1 0
  1. * previously treated for hypertension; n.a. = not available; BMI = body mass index; MAU = microalbuminuria; CHD = coronary heart disease; TIA = transitory ischemic attack; ACEi = ACE inhibitors; ARBs = Angiotensin receptor blockers; CCBs = calcium channel blockers
  2. ** statins and fibrates combined.